A preliminary analysis of insurer participation on the Affordable Care Act’s insurance exchanges said that 31 percent of counties in the U.S. are likely to have a single insurer marketplace in 2017.

Following the decision by the National Government Services to end its local coverage determination for both cellular and tissue-based products, Organogenesis’s PuraPly and PuraPly Antimicrobial products for wound management will be eligible for Medicare coverage and reimbursement in 10 states.

The FDA has announced that Alere has recalled their INRatio and INRatio2 PT/INR monitoring systems.

With rising premiums and the departure of major insurers, there’s been plenty of pessimism towards the Affordable Care Act’s health insurance exchanges, but Princeton University health economist Uwe Reinhardt, PhD, has an even harsher assessment on their future.

In a letter to HHS Secretary Sylvia Burwell, the American Hospital Association (AHA) suggested several possible changes to the Affordable Care Act’s health insurance exchanges, arguing “swift action” is needed to stabilize the markets.

The FDA is advising all U.S. states and territories to screen donated blood and blood components for the Zika virus, a major expansion of screening efforts to prevent spread of the mosquito-borne virus through blood supplies.

Nearly 36 percent of the exchange market rating regions in the U.S. may have only one insurance company participating in the Affordable Care Act’s exchanges, according to an analysis from Avalere.

Thousands of physicians who have been disciplined for serious misconduct, like having sex with patients, are still getting paid by pharmaceutical and medical device companies to act as advisers or promotional speakers, according to an analysis from ProPublica.